|Articles|November 15, 2002
- BioPharm International-11-01-2002
- Volume 15
- Issue 11
Guest Editorial: Back to the Beginning
Author(s)Stefan Schuber
by Stefan Schuber, U.S. Pharmacopeia
Advertisement
Articles in this issue
about 23 years ago
Inside Washington: Major Changes Ahead for FDAabout 23 years ago
Bioinformatics Databases ? Questions of Copyrightabout 23 years ago
European Editor's Report ? An Industry Comes of Ageabout 23 years ago
You Have Failed . . . A Case Study in Warning Letter Remediationabout 23 years ago
Survival Guide to FDA Inspections: Part 3, Responding to ObservationsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
Industry Outlook 2026: Key Forces Transforming Drug Pipelines (Part 2)
4
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
5
